2026 Commercial Plan — Zenvara/Veltarix Franchise
Prepared by VP Commercial. Approved by CCO and CEO. Distribution: executive committee, board package, all commercial team leadership. Annual planning document. Refreshed Q3 mid-year and Q4 forecast update.
Executive summary
The 2026 plan reflects the franchise transition from launch (Year 1 — May 2025 to April 2026) to early commercial maturity (Year 2 — May 2026 to April 2027). Year-2 global net revenue forecast is $580M, with US contribution $410M, EU contribution $130M, and rest-of-world $40M. The plan assumes year-end formulary coverage of 78% (commercial + Medicare Part D) in the US, NICE approval in Q4 2026 driving early UK adoption in early 2027, and steady-state operations across the field force and medical affairs organization.
Year 1 (closed April 2026) booked approximately $260M against an original forecast of $340M — an $80M / 23.5% shortfall driven by four compounding causes: the Aetna step-edit firing at 61% (vs 25-30% modeled), the Tagrisso FLAURA-2 amendment driving 1L mixed-biomarker share-shift, the UHC PA vendor-transition latency, and the late-cycle Florida Medicaid step-edit. The post-mortem and lessons-learned analysis from Year 1 are integrated into the Year 2 plan governance.
The plan presents three scenarios: base case ($580M), upside case ($660M, +14%), and downside case ($480M, -17%). Sensitivities are described in detail below.
Strategic priorities for 2026
1. Recover the UHC commercial book. PA latency normalization is the single most material near-term lever; success here would recover an estimated $40-60M in lost Year 2 revenue.
2. Pull through the Cigna formulary win (effective July 1, 2026). Estimated revenue impact: +$25-35M in Year 2.
3. Hold and grow the Anthem book through Q3 contract renewal. Estimated downside if Anthem closed formulary in 4 states materializes: -$15-25M Year 2.
4. File NICE Module B by September 1, 2026. Successful NICE decision in Q4 2026 enables UK launch in early 2027 — $40-60M Year 3 revenue.
5. ZENITH-2 readout Q3 2026 — go/no-go gate for 2L indication expansion. Positive readout drives the next phase of franchise expansion; negative readout requires repositioning.
6. Resubmit Veltarix Module 4 to G-BA in Q4 2026 with the correct ZVT alignment. Estimated revenue at risk if reassessment fails: -$10-15M Year 3 in Germany.
7. AMCP Format dossier refresh for 2027 PBM contracting cycle. Filed in Q1 2026; supports Q3 PBM negotiations.
8. Patient access program expansion: ZPAP enrollment growth from current 3,200 patients to 7,000 by Q4 2026.
Revenue waterfall — Year 2 base case
US Commercial: $187M (vs Year 1 $96M). Driver: Cigna effective Q3, UHC normalization Q2-Q3, established Anthem and BCBS contracts.
US Medicare Part D: $128M (vs Year 1 $58M). Driver: full year of PDP coverage at 22 of top 25 plans; Humana Gold Plus remains off formulary.
US Medicaid: $19M (vs Year 1 $8M). Driver: Medicaid Managed Care pull-through at 21 states; Florida Medicaid step-edit netted out.
US VA + DoD: $76M (vs Year 1 $28M). Driver: full year of VA National Formulary coverage; DoD TRICARE preferred tier.
US Cash + 340B: $6M (vs Year 1 $4M).
US subtotal: $416M (vs Year 1 $194M). YoY growth: +114%.
EU (Germany direct + UK NICE-conditional + France HAS-conditional): $130M (vs Year 1 $24M). Driver: Germany AMNOG-priced launch full year; UK NICE Q4 2026; France HAS Q1 2027.
RoW (Asia, Latin America, Canada): $40M (vs Year 1 $12M). Driver: Canada CDA-AMC pathway in progress, Japan launch H2 2026.
Total Year 2 base case: $586M global (vs Year 1 $230M global). YoY growth: +154%.
Upside case ($660M global) — drivers
UHC PA latency fully normalized by end of Q2 (recovers $50M).
Anthem closed-formulary states do not materialize (preserves $20M).
Cigna ramps faster than baseline (uplift $10M).
Downside case ($480M global) — drivers
UHC PA latency remains structural through 2026 (loss -$60M).
ESI step-edit imposition in 2027 NPF (loss -$25M starting Q4 2026).
Anthem closed-formulary in 4 states (loss -$20M).
Florida Medicaid step-edit cumulative effect across other states (loss -$10M).
Operating expense plan
Sales force compensation + IC plan: $96M.
Marketing + MAR: $32M.
Medical Affairs + MSL: $42M.
HEOR + Global Value & Access: $24M.
Patient access program (ZPAP + co-pay + bridge): $58M.
External R&D (post-marketing studies, ZEN-RWD, IMpact-2): $84M.
G&A allocation: $26M.
Total operating expenses: $362M.
Year-2 gross margin: 71% (vs 64% Year 1, reflecting volume efficiencies and reduced launch-stage spending).
Field force plan
Year-1 field force: 142 reps + 24 KAMs + 18 MSLs.
Year-2 plan: 145 reps (3 net add for territory backfills), 26 KAMs (2 add to cover community oncology IDNs), 20 MSLs (2 add for European pre-launch coverage).
Net headcount: +9 commercial and medical positions.
Annual fully-loaded cost per rep: $480k. Per KAM: $620k. Per MSL: $580k.
Quarterly cadence
Q1 2026 (May-Jul 2026): Cigna ramp begins July 1. UHC PA recovery in progress. ZENITH-1 5-year update at ASCO Plenary June 7. NICE Module B preparation.
Q2 2026 (Aug-Oct 2026): NICE submission filed September 1. ESI 2027 NPF discussions concluded by August 15. Anthem contract renewal Q3.
Q3 2026 (Nov 2026-Jan 2027): NICE first committee meeting October 14. ZENITH-2 readout target. G-BA Veltarix resubmission Q4.
Q4 2026 (Feb-Apr 2027): NICE final guidance December 23. UK launch preparation. Year-2 close and Year-3 planning kickoff.
Governance
Weekly: launch tracker review (Marco, with cross-functional leads).
Monthly: executive review (CCO + VP Commercial + relevant function heads).
Quarterly: full-team strategy review, including all commercial + medical leadership.
Board: quarterly franchise update covering revenue, share, access, forecast variance, and material strategic decisions.
Year-end: Q4 board package with Year 2 actuals vs plan, Year 3 forecast, and 5-year LCM update.
Risks
Year-2 forecast accuracy: Year 1 missed forecast by 23.5% ($80M) due to a compounding mix of misclassified access friction (Aetna step-edit firing rate underestimated by 2x) and unmodeled competitive share-shift (Tagrisso FLAURA-2 amendment). Year 2 forecasting incorporates the lessons learned but residual uncertainty exists.
ZENITH-2 binary risk: positive vs negative readout has approximately ±$80-100M Year 3 implications.
Competitive landscape: KEYNOTE-WWW Phase 3 readout 2027 is the dominant medium-term competitive risk.
IRA negotiation: long-term but material. Modeled in IRA Negotiation Impact Analysis (1G6…). Year-2 plan does not reflect IRA impact (effective 2034 per current timeline).
Patient access program scale: ZPAP at scale ($58M annual) represents a meaningful gross-to-net concession; sustainability requires continued payer access negotiation.
Cross-references
Zenvara US Launch Plan (1V3…), 2026 US Payer Landscape Brief (1D2…), Lifecycle Management Roadmap (1Q4…), IRA Negotiation Impact Analysis (1G6…), NICE STA Submission Plan (1H3…).